• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Dashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlerts
    Company
    AboutQuantisnow PlusContactJobs
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form 4: Birger Pinhas Doron was granted 20,000 units of Restricted Stock Units

    7/26/21 4:23:01 PM ET
    $PSTI
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $PSTI alert in real time by email
    SEC FORM 4 SEC Form 4
    FORM 4 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

    Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
    or Section 30(h) of the Investment Company Act of 1940
    OMB APPROVAL
    OMB Number: 3235-0287
    Estimated average burden
    hours per response: 0.5
      
    Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).
    1. Name and Address of Reporting Person*
    Birger Pinhas Doron

    (Last) (First) (Middle)
    MATAM PARK, BUILDING #5

    (Street)
    HAIFA L3 3508409

    (City) (State) (Zip)
    2. Issuer Name and Ticker or Trading Symbol
    PLURISTEM THERAPEUTICS INC [ PSTI ]
    5. Relationship of Reporting Person(s) to Issuer
    (Check all applicable)
    X Director 10% Owner
    Officer (give title below) Other (specify below)
    3. Date of Earliest Transaction (Month/Day/Year)
    07/15/2021
    4. If Amendment, Date of Original Filed (Month/Day/Year)
    6. Individual or Joint/Group Filing (Check Applicable Line)
    X Form filed by One Reporting Person
    Form filed by More than One Reporting Person
    Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
    1. Title of Security (Instr. 3) 2. Transaction Date (Month/Day/Year) 2A. Deemed Execution Date, if any (Month/Day/Year) 3. Transaction Code (Instr. 8) 4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5) 5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4) 6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V Amount (A) or (D) Price
    Restricted Stock Units(1) 07/15/2021(2) A 20,000 A $0 20,000 D
    Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
    (e.g., puts, calls, warrants, options, convertible securities)
    1. Title of Derivative Security (Instr. 3) 2. Conversion or Exercise Price of Derivative Security 3. Transaction Date (Month/Day/Year) 3A. Deemed Execution Date, if any (Month/Day/Year) 4. Transaction Code (Instr. 8) 5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5) 6. Date Exercisable and Expiration Date (Month/Day/Year) 7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4) 8. Price of Derivative Security (Instr. 5) 9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4) 10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 11. Nature of Indirect Beneficial Ownership (Instr. 4)
    Code V (A) (D) Date Exercisable Expiration Date Title Amount or Number of Shares
    Explanation of Responses:
    1. Each RSU represents a contingent right to receive one share of the Issuer's common stock.
    2. The shares vest over four years as follows: 12.5% shall vest on the 6 month anniversary of the date of grant and the remaining shares vest in 14 equal instalments every 3 months thereafter.
    /s/ Pinchas Doron Birger 07/26/2021
    ** Signature of Reporting Person Date
    Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
    * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
    ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
    Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
    Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
    Get the next $PSTI alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $PSTI

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $PSTI
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • SEC Form 4: Yanay Yaky was granted 334,821 shares, increasing direct ownership by 23% to 1,760,125 units

      4 - Pluri Inc. (0001158780) (Issuer)

      12/22/22 8:56:45 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Aberman Zami sold $1,940 worth of shares (2,000 units at $0.97), decreasing direct ownership by 0.13% to 1,491,973 units

      4 - Pluri Inc. (0001158780) (Issuer)

      12/22/22 8:52:59 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form 4: Aberman Zami bought $145,109 worth of shares (80,616 units at $1.80)

      4 - PLURISTEM THERAPEUTICS INC (0001158780) (Issuer)

      2/14/22 4:00:49 PM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTI
    SEC Filings

    See more

    $PSTI
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Pluristem Therapeutics Inc. filed SEC Form 8-K: Other Events

      8-K - Pluri Inc. (0001158780) (Filer)

      1/24/23 4:05:21 PM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form D filed by Pluristem Therapeutics Inc.

      D - Pluri Inc. (0001158780) (Filer)

      12/30/22 9:49:07 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluristem Therapeutics Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - Pluri Inc. (0001158780) (Filer)

      12/28/22 4:01:52 PM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Alliance Global Partners initiated coverage on Pluristem Therapeutics with a new price target

      Alliance Global Partners initiated coverage of Pluristem Therapeutics with a rating of Buy and set a new price target of $12.50

      5/4/21 8:35:21 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTI
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13D filed by Pluristem Therapeutics Inc.

      SC 13D - Pluri Inc. (0001158780) (Subject)

      1/4/23 4:17:53 PM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G filed by Pluristem Therapeutics Inc.

      SC 13G - PLURISTEM THERAPEUTICS INC (0001158780) (Subject)

      1/26/22 1:52:20 PM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • SEC Form SC 13G/A filed by Pluristem Therapeutics, Inc. (Amendment)

      SC 13G/A - PLURISTEM THERAPEUTICS INC (0001158780) (Subject)

      6/1/21 7:36:59 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTI
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Independence Realty Trust Appoints Craig Macnab to its Board of Directors

      Waives Option to Classify Board Under Maryland Law Independence Realty Trust, Inc. (NYSE:IRT) ("IRT" or the "Company") today announced the appointment of Craig Macnab to its Board of Directors (the "Board"), effective February 29, 2024. Mr. Macnab brings over 20 years of experience to IRT's Board after serving in various executive and board roles in the REIT industry, including most recently as CEO of National Retail Properties, Inc. (NYSE:NNN) for 13 years. Mr. Macnab's appointment increases the size of IRT's Board to 10 members, including 8 independent directors. In connection with this announcement, the Company has entered into a cooperation agreement with Argosy-Lionbridge Management,

      3/1/24 7:55:00 AM ET
      $AMT
      $IRT
      $NNN
      $VICI
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluri CEO Issues Shareholder Update

      HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company") (formerly known as Pluristem Therapeutics, Inc.), a leading biotechnology company, today issued an update to its shareholders from its Chief Executive Officer and President Yaky Yanay. Pluri: One simple, short word of Greek origin that encapsulates the strategic evolution for our Company. This is our new name. Today, I am proud to share the vision of Pluri: to help pioneer a biotech revolution to create a range of next-generation cell-based products that improve human wellbeing, increase sustainability, and advance solutions to humanity's greatest challenges. In early 2021,

      7/25/22 7:00:00 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluristem Therapeutics Inc. Changes its Name to "Pluri Inc." Reflecting the Company's Strategy to Leverage its Innovative 3D Cell-based Technology Platform to Additional Industries

      As of July 26, 2022, Pluri's stock will trade under the symbol PLURThe new name reflects the Company's strategy to leverage its innovative 3D cell-based technology to a range of fields, developing cell-based products that address various life challenges, while also promoting global wellbeing and sustainabilityVisit our new Company website: www.pluri-biotech.com HAIFA, Israel, July 25, 2022 (GLOBE NEWSWIRE) -- Pluri Inc. (NASDAQ:PLUR) (TASE: PLUR) ("Pluri" or the "Company"), a leading biotechnology company, today announced its name change (NASDAQ:PSTI), reflecting a broader strategy of leveraging its 3D cell expansion technology to develop innovative cell-based products that can be harness

      7/25/22 1:00:00 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care

    $PSTI
    Leadership Updates

    Live Leadership Updates

    See more
    • Independence Realty Trust Appoints Craig Macnab to its Board of Directors

      Waives Option to Classify Board Under Maryland Law Independence Realty Trust, Inc. (NYSE:IRT) ("IRT" or the "Company") today announced the appointment of Craig Macnab to its Board of Directors (the "Board"), effective February 29, 2024. Mr. Macnab brings over 20 years of experience to IRT's Board after serving in various executive and board roles in the REIT industry, including most recently as CEO of National Retail Properties, Inc. (NYSE:NNN) for 13 years. Mr. Macnab's appointment increases the size of IRT's Board to 10 members, including 8 independent directors. In connection with this announcement, the Company has entered into a cooperation agreement with Argosy-Lionbridge Management,

      3/1/24 7:55:00 AM ET
      $AMT
      $IRT
      $NNN
      $VICI
      Real Estate Investment Trusts
      Real Estate
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluristem and Tnuva Appoint Food Tech Veteran Eyal Rosenthal as Chief Executive Officer of their New Joint Venture

      HAIFA, Israel, March 08, 2022 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI), a leading biotechnology company ("Pluristem"), and Tnuva Group ("Tnuva Group" or "Tnuva"), Israel's largest food producer, today jointly announced the appointment of Eyal Rosenthal as Chief Executive Officer of their landmark joint venture to develop, manufacture and commercialize cultured meat. Eyal Rosenthal, Chief Executive Officer(photo credit: Jim Vetter) Mr. Rosenthal is a seasoned entrepreneur and visionary leader in the agritech and food tech industries, serving until recently as venture partner and head of Israeli operations at Finistere Ventures, a pioneering global ventu

      3/8/22 7:12:00 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care
    • Pluristem Appoints Prof. Varda Shalev MD and Mr. Doron Birger to Join its Board of Directors

      HAIFA, Israel, July 19, 2021 (GLOBE NEWSWIRE) -- Pluristem Therapeutics Inc. (NASDAQ:PSTI) (TASE: PSTI), a leading biotechnology company, today announced the Board of Director appointments of Prof. Varda Shalev, a physician, medical researcher, and Professor of Medicine at the Tel Aviv University's School of Public Health, and Mr. Doron Birger, a high-tech industry executive with a background in bringing groundbreaking products to market. Prof. Shalev has more than 30 years of experience working in clinical environments and research settings at the intersection of health and technology. She was the founder and Chief Executive Officer of the KSM Institute of Research and Innovation and Mac

      7/19/21 7:00:00 AM ET
      $PSTI
      Biotechnology: Biological Products (No Diagnostic Substances)
      Health Care